A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin(®) ) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study

De Schepper, Jean; Vanderfaeillie, Johan; Mullis, Primus-Eugen; Rooman, Raoul; Robertson, Anna; Dilleen, Maria; Gomez, Roy; Wollmann, Hartmut A (2016). A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin(®) ) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study. Clinical endocrinology, 84(3), pp. 353-360. Blackwell Scientific Publications 10.1111/cen.12968

Text cen12968.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (188kB) | Request a copy

OBJECTIVE

In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognitive functioning in very young (<30 months), short-stature children born SGA.

DESIGN

A 2-year, randomized controlled, multicentre study (NCT00627523; EGN study), in which patients received either GH treatment or no treatment for 24 months.

PATIENTS

Children aged 19-29 months diagnosed as SGA at birth, and for whom sufficient early growth data were available, were eligible. Patients were randomized (1:1) to GH treatment (Genotropin(®) , Pfizer Inc.) at a dose of 0·035 mg/kg/day by subcutaneous injection, or no treatment.

MEASUREMENTS

The primary objective was to assess the change from baseline in height standard deviation score (SDS) after 24 months of GH treatment.

RESULTS

Change from baseline in height SDS was significantly greater in the GH treatment vs control group at both month 12 (1·03 vs 0·14) and month 24 (1·63 vs 0·43; both P < 0·001). Growth velocity SDS was significantly higher in the GH treatment vs control group at 12 months (P < 0·001), but not at 24 months. There was no significant difference in mental or psychomotor development indices between the two groups.

CONCLUSIONS

GH treatment for 24 months in very young short-stature children born SGA resulted in a significant increase in height SDS compared with no treatment.

Interest & Impact

Downloads

0 since deposited on 02 May 2016
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item